Living with bipolar disorder

Expert Review of Neurotherapeutics

Volumn 4, Issue 6 SUPPL. 2, 2004, Pages

  Kasper, Siegfried F ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bipolar disorder; Quality of life; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUOXETINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; ZIPRASIDONE;

AGRANULOCYTOSIS; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED STUDY; DIZZINESS; EXTRAPYRAMIDAL SYMPTOM; FAMILY LIFE; HEADACHE; HUMAN; HYPERPROLACTINEMIA; ILLNESS INTRUSIVE RATING SCALE; LEISURE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MONOTHERAPY; NAUSEA; PAIN; PATIENT EDUCATION; PHYSICAL DISABILITY; QUALITY OF LIFE; RASH; RATING SCALE; SHEEHAN DISABILITY SCALE; SOCIAL DISABILITY; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREMOR; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COGNITION DISORDERS; COGNITIVE THERAPY; FOLLOW-UP STUDIES; HUMANS; QUALITY OF LIFE;

EID: 8344221915     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.4.6.S9     Document Type: Conference Paper

References (51)

1. Suppes T, Leverich GS, Keck PE et al. The Stanley Foundation Bipolar Treatment Outcome Network. II. Demographics and illness characteristics of the first 261 patients. J. Affect. Disord. 67, 45-59 (2001).
2. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J. Clin. Psychiatry 64, 161-174 (2003). Large survey of US National Depressive and Manic-Depressive Association members that found a significant negative impact of bipolar disorder on families, social relationships, and employment.
3. Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM. The National Depressive and Manic-Depressive Association (NMDA) survey of bipolar members. J. Affect Disord. 31, 281-294 (1994).
4. Baldessarini RJ, Tondo L, Hennen J, Floris G. Latency and episodes before treatment: response to lithium maintenance in bipolar I and II disorders. Bipolar Disord. 1, 91-97 (1999).
5. Robb JC, Cooke RG, Devins GM et al. Quality of life and lifestyle disruption in euthymic bipolar disorder. J. Psychiatry Res. 31, 509-517 (1997). Impact of bipolar illness is at least as significant as several chronic medical conditions, such as multiple sclerosis and rheumatoid arthritis. Quality of life in bipolar disorder is impacted even during periods of euthymia.
6. Dalton EJ, Carter TD, Mundo E et al. Suicide risk in bipolar patients: the role of co-morbid substance use disorders. Bipolar Disord. 5, 58-61 (2003).
7. Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Genet. Psychiatry 59, 530-537 (2002). In 146 patients with bipolar I disorder, on average, symptoms were present almost half the time during a follow-up period of more than 12 years. Depression was the most frequent symptom during this period (32%), followed by mania or hypomania (9%) and rapid cycling or mixed episodes (6%).
8. Calabrese JR, Hirschfeld RM, Reed M et al. Impact of bipolar disorder on a US community sample. J. Clin. Psychiatry 64, 425-432 (2003). Large survey-based study in which performance of work-related, leisure, and interpersonal activities were significantly negatively impacted in individuals positive for bipolar disorder on the Mood Disorder Questionnaire compared with those who were negative for bipolar disorders.
9. Hirschfeld RM, Williams JB, Spitzer RL et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am. J. Psychiatry 157, 1873-1875 (2000).
10. Morselli PL, Elgie R. GAMIAN-Europe/ BEAM survey I. Global analysis of a patient questionnaire circulated to 3450 members of 12 European advocacy groups operating in the field of mood disorders. Bipolar Disord. 5, 265-278 (2003). A patient survey carried out to gain a better understanding of what it is like to live with bipolar disorder that found patients experience a high degree of stigmatization and difficulties in obtaining employment despite high academic achievement.
11. Vojta C, Kinosian B, Click H et al. Self-reported quality of life across mood states in bipolar disorder. Compr. Psychiatry 42, 190-195 (2001). Depressive symptoms appear to be the primary determinant of quality of life in bipolar disorder, although mania and hypomania are also associated with a reduced, rather than increased, sense of well being and quality of life.
12. Rubinsztein JS, Michael A, Paykel ES et al. Cognitive impairment in remission in bipolar affective disorder. Psychol. Med. 30, 1025-1036 (2000).
13. Denicoff KD, Ali SO, Mirsky AF et al. Relationship between prior course of illness and neuropsychological functioning in patients with bipolar disorder. J. Affect. Disord. 56, 67-73 (1999).
14. Zubieta JK, Huguelet P, O'Neil RL et al. Cognitive function in euthymic bipolar I disorder. Psychiatry Res. 102, 9-20 (2001).
15. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York: Oxford University Press (1990).
16. Hirschfeld RMA, Clayton PJ, Cohen I et al. Practice guideline for the treatment of patients with bipolar disorder. Am. J. Psychiatry 51(Suppl. 12), 1-36 (1994).
17. Keck PE, McElroy SL, Strakowski SM et al. Compliance with maintenance treatment in bipolar disorder. Psychopharmacol. Bull 3, 87-91 (1997).
18. Goldberg JF, Ernst CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J. Clin. Psychiatry 63, 985-991 (2002).
19. Franchini L, Zanardi R, Smeraldi E et al. Early onset of lithium prophylaxis as a predictor of good long-term outcome. Eur. Arch. Psychiatry Clin. Neurosci. 249, 227-230 (1999).
20. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J. Clin. Psychiatry 60(Suppl. 2), 77-84 (1999).
21. Kasper S. Issues in the treatment of bipolar disorder. Eur. Neuropsychopharmacol. 13(Suppl. 2), S37-S42 (2003).
22. McElroy SL, Keck Jr, PE. Pharmacological agents for the treatment of acute bipolar mania. Biol. Psychiatry 48, 539-557 (2000).
23. Nemeroff CB. An ever-increasing Pharmacopeia for the management of patients with bipolar disorder. J. Clin. Psychiatry 61(Suppl. 13), 19-25 (2000).
24. Thase ME, Sachs GS. Bipolar depression: pharmacotherapy and related therapeutic strategies. Biol. Psychiatry 48, 558-572 (2000).
25. Gyulai L, Bowden CL, McElroy SL et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 28, 1374-1382 (2003).
26. Revicki DA, Paramore LC, Sommerville KW et al. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical costs outcomes. J. Clin. Psychiatry 64, 288-294 (2003).
27. Post RM. Mood disorders: treatment of bipolar disorders. In: Kaplan and Sadocks Comprehensive Textbook of Psychiatry, Seventh Edition. Sadock BJ, Sadock VA (Eds). Williams & Wilkins, NY, USA 1385-1430 (2000).
28. Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Genet. Psychiatry 60, 392-400 (2003).
29. Calabrese JR, Bowden CL, Sachs G et al.; Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J. Clin. Psychiatry 64, 1013-1024 (2003).
30. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in out-patients with bipolar I depression. Lamictal 602 Study Group. J. Clin. Psychiatry 60, 79-88 (1999).
31. Namjoshi MA, Rajamannar G, Jacobs T et al. Economic, clinical, and quality of life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial. J. Affect. Disord. 69, 109-118 (2002).
32. Shi L, Namjoshi MA, Zhang F et al. Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. Int. Clin. Psychopharmacol. 17, 227-237 (2002).
33. Kasper S, Stamenkovic M, Letmaier M, Schreinzer D. Atypical antipsychotics in mood disorders. Int. Clin. Psychopharmacol. 17(Suppl. 3), S1-10 (2002).
34. Kasper S, Attarbaschi T. Treatment options for bipolar mania. Clin. Approach Bipolar Disord. 3, 24-32 (2003).
35. Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Genet. Psychiatry 60, 1079-1088 (2003).
36. Calabrese J, Macfadden W, McCoy R, Minkwitz M, Wilson E, Mullen J. Double-blind, placebo-controlled study of quetiapine in bipolar depression. 157th Annual Meeting of the American Psychiatric Association. NY, USA. 1-6th May (2004).
37. Kusumaker V. Antidepressants and antipsychotics in the long-term treatment of bipolar disorder. J. Clin. Psychiatry 63(Suppl. 10), 23-28 (2002).
38. Sachs G, Chengappa KNR, Suppes T et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 6, 213-223 (2004).
39. Jones M, Huizar K. Quetiapine monotherapy for acute mania associated with bipolar disorder (STAMP 1 and STAMP 2). Bipolar Disord. 5, 57 (2003) (Abstract P95).
40. White RE. Antipsychotic compliance evaluation. Int. J. Neuropsychopharmacol. 5(Suppl. 1), S120 (2002) (Abstract).
41. Namjoshi MA et al. A review of health-related quality of life literature in bipolar disorder. J. Affect. Disord. 69, 109-118 (2002).
42. Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J. Clin. Psychiatry 61, 804-808 (2000).
43. Möller HJ, Grunze H. Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? Eur. Arch. Psychiatry Clin. Neurosci. 250, 57-68 (2000).
44. Kasper S. Bipolar disorder: a new field for rational polypharmacy. In: Bipolar Disorder. Evidence and Experience in Psychiatry. Maj M (Ed.) Wiley & Sons Ltd, Chichester, UK 275-276 (2002).
45. Kasper S, Tauscher J, Aschauer H et al. Bipolare Störungen. Medikamentöse Therapie. Konsensus. Statement -State of the Art 2003. Clin. Cum. Psy. Sonderausgabe (2003).
46. Craighead WE, Miklowitz DJ. Psychosocial interventions for bipolar disorder. J. Clin. Psychiatry 61 (Suppl. 13), 58-64 (2000).
47. Kasper S, Zohar J. Pharmacotherapy of bipolar depression. In: Decision Making in Psychopharmacology. Kasper S, Zohar J, Stein DJ (Eds) Martin Dunitz, London, UK, 13-23 (2002).
48. Dogan S, Sabanciogullari S. The effects of patient education in lithium therapy on quality of life and compliance. Arch. Psychiatry Nurs. 17, 270-275 (2003).
49. Patelis-Siotis I. Cognitive-behavioral therapy: applications for the management of bipolar disorder. Bipolar Disord. 3, 1-10 (2001).
50. Miklovitz DJ, Richards JA, George EL et al. Integrated family and individual therapy for bipolar disorder: results of a treatment development study. J. Clin. Psychiatry 64, 182-191 (2003).
51. Colom F, Vieta E, Reinares M, Martinez-Aran A, Torrent C, Goikolea JM, Gasto C. Psychoeducation efficacy in bipolar disorders: beyond compliance enhancement. J. Clin. Psychiatry 64, 1101-1105 (2003).